700 patients110,866 observations180 daysLIVE
← Patients

Patient P-02401

Synthetic patientMETA-24 · Day 175 · 55–64 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
78%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 started — Baseline state S14
  2. Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 71 GI-04 recommended — GI Support Protocol GI-04
  4. Day 72 Patient accepted — Started GI-04 in the companion
  5. Day 80 GI symptom burden −28% vs expected — GI Support Protocol GI-04
  6. Day 86 Tolerance state changed — Unstable → Improving
  7. Day 93 ME-01 recommended — Monitoring Escalation ME-01
  8. Day 94 Patient accepted — Started ME-01 in the companion
  9. Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 70.

Primary contributors, last 14 days
  • GI instability+5
  • Toxicity+4

What helped?

  • GI Support Protocol GI-04Day 71
    Result: symptom burden −28%
  • Monitoring Escalation ME-01Day 93
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
67%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 69% showed improvement
  • median effect visible after 6 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
24 min
improving · +2.6 vs previous 14 d
Sleep duration
Wearable
6 h
stable · +0.1 vs previous 14 d
Energy level
Daily log
2.8/10
improving · +0.1 vs previous 14 d
Steps
Wearable
2,960
improving · +390 vs previous 14 d
GI burden
Companion
63.1/100
stable · +1.6 vs previous 14 d
Adherence
Companion
50.8 %
stable · +1.3 vs previous 14 d
Sleep quality
Wearable
33.2/100
worsening · -2.9 vs previous 14 d
Glucose, CGM daily mean
CGM
143 mg/dL
stable · -0.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 30 from the failing basin, 63 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    59% improved among 32 similar · onset 10 d · confidence 80%
  • SC-12 Supportive Compound
    69% improved among 26 similar · onset 6 d · confidence 80%
  • CR-01 Clinician Review
    100% improved among 6 similar · onset 5 d · confidence 80%
  • More protein
    GI -3.6 next day on high-intake days · n 17
Would not help
  • Keep histamine low
    GI +3.3 next day on high-intake days · n 19
  • Keep fat low
    GI +3.2 next day on high-intake days · n 21
  • Keep ultra-processed low
    GI +2.9 next day on high-intake days · n 20
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -3.6supporter · 95%
  • Histamine load
    +3.3detractor · 95%
  • Dietary fat load
    +3.2detractor · 95%
  • Ultra-processed food
    +2.9detractor · 95%
  • Alcohol
    +1.7no signal · 49%
  • Simple carbohydrates
    -0.6no signal · 18%
  • Insoluble fibre
    -0.4no signal · 15%
  • Caffeine
    +0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 63 and rising
    • WearableSleep 6.0 h, below personal baseline
  • Butyrate / short-chain fatty acid production ↓80
    • MicrobiomeButyrate capacity 33/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling ↓70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 55
  • Autonomic recovery ↓65
    • WearableResting HR 72 bpm
    • Wearable2,960 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure ↑20
    • BloodToxicity index 47
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Intermediate metabolizer
    Expected exposure
  • GLP1R rs6923761 A
    Altered receptor sensitivity
Microbiome
Shannon diversity 3.1 · butyrate capacity 33/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
46 ms
Sleep
6.2 h
Steps
2,813
Resting HR
69 bpm
Daily log: GI score 63, nutritional resilience 40, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0201852%S01GI-04improved46
P-0241049%S01GI-04improved55
P-0205434%S01CR-01improved57
P-0240932%S01SC-12no change54
P-0230723%S01——55
P-0259823%S01——53
P-0243722%S01——64
P-0204121%S01——27
P-0208721%S01BR-03no change40
P-0227621%S01——57
P-0255021%S01——70
P-0256821%S01——51